16,000 Americans live with ALS, yet only 2 FDA-approved disease-modifying drugs exist. A new experimental compound shows neuroprotective promise in laboratory models.

Alzheimer's disease begins many years before memory problems become obvious. People in the early ("prodromal") stage have memory complaints but are still independent in daily life. At present there is no treatment that prevents this stage from progressing to dementia. Olive oi...

Abstract Multiple sclerosis (MS) is an autoimmune inflammatory disorder that affects the central nervous system (CNS) and has been extensively studied in experimental autoimmune encephalomyelitis (EAE) animal models. AG490, which has potent neuroprotective activity, is used to investigate immune ...

BCG vaccination produces measurable brain immune changes lasting 12 months, establishing a mechanistic basis for neuroprotection against Alzheimer's disease.

Aging dogs often exhibit subtle shifts in behavior: they may forget long-standing routines, experience disrupted sleep patterns, or appear disoriented. These changes are typical signs of cognitive decline. While aging is inevitable, adjusting a senior pet's diet to include neuroprotective nutrients can help maintain brain cell integrity and mental clarity. Certain nutrients target specific biological processes to support the aging brain: Omega-3 Fatty Acids (DHA): Docosahexaenoic acid is a primary component of brain cell membranes. Found heavily in fish oil, it supports memory and learning while reducing systemic inflammation that can hinder cognitive speed. Vitamin E: This antioxidant protects neurons from oxidative stress and free radical damage, while simultaneously supporting the immune system in older dogs. B-Vitamins (B6, B12, and Folic Acid): These are essential for nerve impulse transmission and cellular energy metabolism, ensuring the nervous system remains stable. Antioxidants: Compounds found in blueberries, spinach, and kale help neutralize damage to brain tissues. Coenzyme Q10: By aiding cellular energy production, CoQ10 can improve alertness and potentially soften the symptoms of cognitive dysfunction. L-Carnitine: This amino acid allows brain cells to utilize fats for energy, which can lead to better concentration and memory retention. Alpha-Lipoic Acid: An antioxidant that regenerates other antioxidants, such as vitamins C and E, supporting mitochondrial health and slowing the pace of brain aging. Phosphatidylserine: This phospholipid facilitates communication between neurons, directly impacting a senior dog's ability to focus and process new information. Medicinal Mushrooms: Varieties like Turkey Tail contain polysaccharides that combat the inflammation and oxidative stress central to brain aging. Balanced nutrition, moderate physical activity, and mental stimulation form the foundation of senior care. However, introducing supplements or making abrupt dietary changes requires professional oversight. A veterinarian must evaluate the dog's current health status and blood work to determine which specific nutrients are necessary and safe for the individual animal.

Axonal degeneration is a principal driver of irreversible neurological disability in multiple sclerosis (MS), yet current treatments fail to target this neurodegenerative phase directly. Sterile alpha and TIR domain-containing protein 1 (SARM1) has emerged as an executioner of programmed axon des...

From microbial metabolites to inflammation and the blood-brain barrier, researchers trace how Mediterranean eating could influence neurodegeneration, while exposing a crucial gap in the evidence. Review: Gut Microbiome-Mediated Neuroprotective Effect of the Mediterranean Diet: A Narrative Review of Cognitive Aging, Alzheimer’s Disease, and Parkinson’s Disease. Image Credit: LipeBorges_Foto / Shutterstock A recent narrative review published in the journal Nutrients found that direct human evidence showing that Mediterranean diet (MD)-induced microbiome changes mediate its potential neuroprotective effects remains limited. Background Neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) comprise a growing disease segment that imposes a substantial burden on the patient as well as on societal, economic, and public health resources. With no curative therapies in sight, there is a need for strategies to preserve brain health and prevent or delay the onset and progression of disease. The MD is among the most promising lifestyle modifications for reducing the risk of cognitive decline. It is characterized by high intakes of fruits, vegetables, whole grains, legumes, nuts, and seeds, with extra-virgin olive oil (EVOO), fish, poultry, and fermented dairy products in moderation. This provides high levels of bioactive compounds, including omega-3 fatty acids, vitamins, and minerals, that mitigate oxidative...

Mechanical loading of the tibia improves survival and recovery after brain surgery in mice and pigs. This bone–brain axis is mediated by osteocyte PIEZO1, which triggers the release of neuroprotective...

Mechanical loading of the tibia improves survival and recovery after brain surgery in mice and pigs. This bone–brain axis is mediated by osteocyte PIEZO1, which triggers the release of neuroprotective...

Mechanical loading of the tibia improves survival and recovery after brain surgery in mice and pigs. This bone–brain axis is mediated by osteocyte PIEZO1, which triggers the release of neuroprotective...

PubMed link

Read the full paper: Neuroprotective effect of a selective peroxisome proliferator-activated receptor alpha modulator in murine cerebral ischemia

Read the full paper: Unveiling Neuroprotective Effects of a Triazole-Based Compound in SH-SY5Y Alzheimer's Disease-Induced Cell Model

Background Growing evidence implicates gut microbiota (GM) dysbiosis in Alzheimer’s disease (AD) pathogenesis via the gut-brain axis. Dysbiosis contributes to neuroinflammation, amyloid-β deposition, tau hyperphosphorylation, blood-brain barrier disruption, and cognitive decline. Synbiotics (combinations of probiotics and prebiotics) offer a promising strategy to modulate GM, potentially ameliorating these AD hallmarks through multiple mechanisms including enhanced production of neuroprotective short-chain fatty acids (SCFAs), reduced inflammation, improved gut barrier integrity, and immunomodulation. Objective This review critically evaluates the current evidence on the therapeutic potential of synbiotics for AD. It aims to synthesize findings from preclinical and clinical studies regarding the efficacy of synbiotics in improving cognitive function and AD pathology, elucidate the underlying biological mechanisms including GM modulation, SCFA production, immune regulation, and gut-brain signaling, and identify key challenges and future research directions for translating GM-targeted interventions into effective AD therapies. Conclusion Synbiotics demonstrate significant potential, particularly in early AD, by improving cognitive domains, reducing neuroinflammation and AD biomarkers, and modulating beneficial microbial metabolites. However, challenges include confounding factors, unresolved questions about causality, inconsistent results in advanced disease, and insufficient large-scale human trials. Future success hinges on rigorous longitudinal randomized controlled trials integrating multi-omics approaches, advanced in vitro models, and personalized strategies considering baseline microbiota and host genetics. While not a standalone cure, synbiotics represent a valuable component within multi-target therapeutic approaches aimed at modulating the gut-brain axis to slow AD progression.

Simple SummaryOxaliplatin is an important chemotherapy drug, but it can damage sensory nerves and cause lasting numbness, neuropathic pain, and manual dexterity/gait instability.

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced the establishment of a dedicated Alzheimer's Disease Scientific Advisory Board (SAB). The SAB brings together leading global experts with complementary expertise across Alzheimer’s disease biology, biomarkers, cognitive assessment, neurophysiology, genetics, data science and neurological drug development and will provide scientific and clinical guidance as Galimedix advances its Alzheimer’s disease program through clinical development. SAB members include: Andreas Busjahn, PhD, Founder and Managing Director of HealthTwiSt, Berlin, is a biostatistics and data-science expert with broad experience in biomedical research. Willem de Haan, MD, PhD, Neurologist and Senior Researcher at Alzheimer Center Amsterdam, Amsterdam UMC, specializes in neuronal network dysfunction in Alzheimer’s disease and EEG-based measures of brain connectivity and treatment effects. John E. Harrison, PhD, Professor at King’s College London and at Amsterdam UMC, is Chair of the Scientific Advisory Board of Scottish Brain Sciences and Clinical Vice President at Signant Health, with long-standing expertise in cognitive assessment in dementia. Charlotte Teunissen, PhD, Professor of Neurochemistry at Amsterdam UMC, is a leading expert in fluid biomarkers for neurological diseases and...

Implications of menopause hormone therapy (MHT) for cognitive aging remain unclear despite decades of research. Potential reasons include insufficient consideration of MHT type, despite notable pharma...

Mechanical loading of the tibia improves survival and recovery after brain surgery in mice and pigs. This bone–brain axis is mediated by osteocyte PIEZO1, which triggers the release of neuroprotective...